TAILORED MEDS LIMITED

Executive Summary

Tailored Meds Limited is a dormant and non-trading entity with minimal financial substance and no operational history. The company lacks the financial strength and cash flow necessary to support credit risk, leading to a recommendation to decline credit facilities at this time. Future credit consideration should await evidence of business activity and financial performance.

TAILORED MEDS LIMITED - Analysis Report

Company Number: 13887556

Analysis Date: 2025-07-20 17:00 UTC

1. Credit Opinion:
   DECLINE. Tailored Meds Limited is a dormant company with no trading activity or financial performance to assess. The accounts show only nominal share capital and net assets of £100 over multiple years, indicating no operational business or income generation. Without any revenue, cash flow, or trading history, the company lacks the ability to service debt or meet financial obligations. Thus, from a credit perspective, the risk is high due to absence of financial substance or proven cash flow.

2. Financial Strength:
   The balance sheet is minimal and static, showing only £100 in shareholders' funds and net assets consistently over three years. There are no fixed or current assets, no liabilities, and no retained earnings or reserves. This reflects a company that has not commenced trading or invested in business assets. Financial strength is effectively non-existent since the entity holds no tangible or liquid assets beyond the nominal share capital.

3. Cash Flow Assessment:
   As a dormant company, there are no reported cash flows from operations, investing, or financing activities. The absence of current assets or liabilities means there is no working capital. The company’s liquidity position cannot be assessed meaningfully but is presumed to be negligible, relying solely on the initial share capital. There is no evidence of cash generation or capacity to meet ongoing expenses or credit commitments.

4. Monitoring Points:

• Monitor for commencement of trading and subsequent filing of full accounts reflecting operating performance and cash flows.
• Watch for changes in net assets or shareholder funds indicating capital injections or business activity.
• Track director appointments and any changes in control that might signal restructuring or new business plans.
• Review future accounts for evidence of revenue, profitability, and liquidity improvements before reconsidering credit facilities.